Author

Holly H. C. Kimko

AstraZeneca (United States)ORCID 0000-0003-1456-4862Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Aimée ParkeriD· 1 shared Aleksander S. PopeliD· 1 shared Ambra Bianco· 1 shared Carmen PiniD· 1 shared Carrie A. DuckworthiD· 1 shared David Mark PritchardiD· 1 shared Ferran JardíiD· 1 shared Hanwen WangiD· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Aimée ParkerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems BiologyeLifePeer-reviewedDec 8, 2023

Homeostasis, injury and recovery dynamics at multiple scales in a self-organizing intestinal crypt

Louis Gall, Carrie A. Duckworth, Ferran Jardí…·Carmen Pin

This paper presents a multi-scale agent-based model of intestinal crypt dynamics, showing how signaling pathways and feedback loops govern homeostasis, injury, and recovery.

11 citations

experimental assay

𝕏 PostBluesky

Systems Biologynpj Precision OncologyPeer-reviewedJun 8, 2023

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition

Hanwen Wang, Theinmozhi Arulraj, Holly H. C. Kimko, Aleksander S. Popel

The paper uses a QSP model to generate virtual patients for NSCLC and predicts response to PD-L1 inhibition using immunogenomic data.

32 citationstop 5%

humanbulk RNA-seq

𝕏 PostBluesky